Abstract
Immune related adverse events (irAEs) after immune checkpoint blockade (ICB) therapy occur in a significant proportion of cancer patients. To date, the circulating mediators of ICB-irAEs remain poorly understood. Using non-targeted mass spectrometry, here we identify the circulating bio-active lipid linoleoyl-lysophosphatidylcholine (LPC 18:2) as a modulator of ICB-irAEs. In three independent human studies of ICB treatment for solid tumor, loss of circulating LPC 18:2 preceded the development of severe irAEs across multiple organ systems. In both healthy humans and severe ICB-irAE patients, low LPC 18:2 was found to correlate with high blood neutrophilia. Reduced LPC 18:2 biosynthesis was confirmed in preclinical ICB-irAE models, and LPC 18:2 supplementation in vivo suppressed neutrophilia and tissue inflammation without impacting ICB anti-tumor response. Results indicate that circulating LPC 18:2 suppresses human ICB-irAEs, and LPC 18:2 supplementation may improve ICB outcomes by preventing severe inflammation while maintaining anti-tumor immunity.
Competing Interest Statement
S.T., J.D.W, M.J. and S.S. have financial interest in Sapient Bioanalytics, LLC.
Funding Statement
This work was supported by National Institutes of Health (NIH) grant nos U01DE028227 (J.S.G., S.S.), U54AG065141 (M.J., S.C., S.S.) and R01CA273230 (S.K., S.C., M.J., S.S.); S10OD020025 and R01ES027595 (M.J.); NIH P01DK46763 (M.K.); NIH U01CA233364 (A.A.P.); T32GM007752 and F31CA236405; a Tulie and Rickie Families SPARK award (I.T.M.) and an American Cancer Society Postdoctoral Fellowship PF-20-132-01-LIB (M.A.M.). M.G.N. was supported by an ERC Advanced grant (833247) and Spinoza grant of the Netherlands Organization for Scientific Research. T.N. was supported by the Research Council of Finland (Grants 321351 and 354447) and the Sigrid Juselius Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The North West-Greater Manchester Central Research Ethics Committee of Southampton University Hospitals NHS Foundation Trust gave ethical approval for the work included in Cohort 1 ("Southampton Ipilimumab") The University of California San Diego Human Research Protections Program Institutional Review Board of UC San Diego and Moores Cancer Center gave ethical approval for the work included in Cohort 2 ("Moores Cancer Center Mixed ICB") The Institutional Review Board of Yale University gave ethical approval for the work included in Cohort 3 ("Yale Pembrolizumab", NCT02407171) The Ethical Committee of Radboud University Nijmegen gave ethical approval for the work included from the Human Functional Genomics Project ("500FG") Coordinating Ethical Committee of the Helsinki and Uusimaa Hospital District gave ethical approval for the work included from the Finland National FINRISK study ("FINRISK 2002")
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data supporting the findings of this study, including patient information and demographics, LC-MS feature quantitative measurement and raw LC-MS data, are contained within the article or available within Supplementary Information.